HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $44 Price Target

Benzinga · 05/13/2024 10:33
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $44 price target.